As previously reported, Wedbush analyst David Nierengarten downgraded Stemline to Neutral from Outperform, while keeping $18 price target on the shares, as he believes the positive launch trajectory of ELZONRIS and expectations for label expansion are fully valued at these levels. Next up, the analyst looks forward to additional ELZONRIS clinical updates in chronic myelomonocytic leukemia and myelofibrosis at ASCO May 29-June 4, as well as a potential regulatory update regarding the indications following the company's planned registration discussions with the FDA mid-2019.